Deb Kelly is a pioneering leader in biomedical research, known for her expertise in molecular biophysics, computational modeling, and high-resolution imaging to advance translational medicine. As Executive Director of Structural Oncology LLC and a professor at Penn State University, she has led groundbreaking research in cancer and viral health threats, integrating artificial intelligence and bioinformatics to drive drug discovery and clinical decision-making. With over 15 years of experience managing multidisciplinary teams, securing millions in research funding, and mentoring early-career professionals, Kelly’s work has had a lasting impact on biomedical science. Her strategic leadership, innovative research, and commitment to mentorship continue to shape the future of medical advancements and therapeutic development.

Ryan K. Stansfield is a seasoned leader with over 23 years of experience in small molecule drug discovery and development. Currently serving as Director of DMPK-Toxicology at 858 Therapeutics, he has successfully led teams through critical phases of drug development, including managing IND-enabling toxicology studies and building high-performing scientific teams. Stansfield is recognized for his deep expertise in ADME, safety pharmacology, and toxicology, as well as his strategic ability to drive projects from discovery to clinical trials. Throughout his career, he has demonstrated exceptional communication skills, collaborating across functions and ensuring timely, rigorous data to support regulatory submissions. With a proven track record in managing budgets, experimental design, and in-licensing diligence, Stansfield has contributed to the successful advancement of multiple therapeutic candidates.

Peter Payne is a highly accomplished executive with over 30 years of leadership experience in the pharmaceutical, biotechnology, and contract research organization (CRO) industries. Known for his integrity and results-driven approach, Peter has successfully led organizations through periods of significant growth and transformation. With deep expertise in drug development, clinical trials, and corporate strategy, he has built a strong reputation for driving innovation and strategic partnerships. His leadership spans notable roles, including Vice President at Optum, President of Gennaker Bio, and CEO at multiple biotech companies. Peter’s ability to communicate complex strategies and foster cross-functional collaboration has made him a respected figure in the life sciences industry.

Michael Ekstut is a seasoned business leader with over 30 years of experience in the life sciences industry, specializing in drug discovery, development, and regulatory strategy. He has held senior leadership roles at industry-leading companies, including Certara, where he guided the company’s commercial and product strategy in the regulatory and access sector. Michael is known for his strategic vision and ability to drive innovation, optimizing clinical development programs and supporting biopharma companies in navigating complex regulatory landscapes. His deep expertise in business consulting, technology, and operational management has enabled him to successfully advise executives and investors across pharmaceuticals, biotechnology, and medical devices. Currently serving as a Senior Advisor at InSilicoTrials, Michael continues to leverage his vast experience to help organizations maximize the impact of their clinical development programs and investments.

Quynh Ton is a dedicated and resilient molecular and cellular developmental biologist with over 10 years of experience in the biotech industry. Known for her integrity and commitment to improving patient care, Quynh combines her extensive knowledge in drug discovery, gene therapy, and antibody development with a proven track record in business development. She has successfully secured significant contracts, demonstrating her strategic acumen and ability to drive initiatives within her field. Quynh's exceptional communication skills enable her to convey complex scientific concepts clearly, fostering collaboration across diverse teams and stakeholders. Her passion for advancing scientific knowledge and delivering impactful solutions positions her as a valuable asset in any organization.